EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

N 6 ‐methyladenosine‐mediated upregulation of LNCAROD confers radioresistance in esophageal squamous cell carcinoma through stabilizing PARP1

Xiaobo Shi iD, Xiaozhi Zhang, Xinran Huang, Ruijuan Zhang, Shupei Pan, Shan Huang, Yuchen Wang, Yue Ke, Wei Guo, Xiaoxiao Liu, Yu Hao, You Li und 5 weitere

Clinical and Translational Medicine · 2024-10 · 14 (10)

DOI: 10.1002/ctm2.70039 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Medicine, online erschienen am 05.10.2024. Verfasst von Xiaobo Shi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Hauptthemen laut MEDLINE: Adenosine, Esophageal Squamous Cell Carcinoma, RNA, Long Noncoding, Esophageal Neoplasms. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Radiotherapy is a primary therapeutic modality for esophageal squamous cell carcinoma (ESCC), but its effectiveness is still restricted due to the resistance of cancer cells to radiation. Long non‐coding RNAs (lncRNAs) and N 6 ‐methyladenosine (m6A) have been shown to play significant roles in tumour radioresistance. However, the precise manifestation and role of m6A‐modified lncRNAs in ESCC radioresistance remain unclear.

Methods

Bioinformatics analysis was conducted to identify m6A‐modified lncRNAs implicated in the radioresistance of ESCC. A series of functional experiments were performed to investigate the function of LNCAROD in ESCC. Methylated RNA immunoprecipitation, chromatin isolation by RNA purification‐mass spectrometry, RNA immunoprecipitation, and co‐immunoprecipitation experiments were performed to explore the mechanism of m6A‐mediated upregulation of LNCAROD expression and the downstream mechanism enhancing the radioresistance of ESCC. The efficacy of LNCAROD in vivo was assessed using murine xenograft models.

Results

Herein, we identified LNCAROD as a novel METTL3‐mediated lncRNA that enhanced radioresistance in ESCC cells and was post‐transcriptionally stabilised by YTHDC1. Moreover, we confirmed that LNCAROD prevented ubiquitin‐proteasome degradation of PARP1 protein by facilitating PARP1‐NPM1 interaction, thereby contributing to homologous recombination‐mediated DNA double‐strand breaks repair and enhancing the radiation resistance of ESCC cells. Silencing LNCAROD in a nude mouse model of ESCC in vivo resulted in slower tumour growth and increased radiosensitivity.

Conclusion

Our findings enhance the understanding of m6A‐modified lncRNA‐driven machinery in ESCC radioresistance and underscore the significance of LNCAROD in this context, thereby contributing to the development of a potential therapeutic target for ESCC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenosineEsophageal Squamous Cell CarcinomaRNA, Long NoncodingEsophageal NeoplasmsRadiation TolerancePoly (ADP-Ribose) Polymerase-1Up-RegulationHumansAnimalsMiceCell Line, TumorMice, NudeMethyltransferasesGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

LNCARODN6‐methyladenosinePARP1esophageal squamous cell carcinomaradioresistance

Substanzen

AdenosineN-methyladenosineRNA, Long NoncodingPoly (ADP-Ribose) Polymerase-1PARP1 protein, humanMethyltransferases

Autor:innen und Institutionen

  • Department of Radiation Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • Department of Radiation Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • Department of Peripheral Vascular, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

ORCID-Profile: Xiaobo Shi, Xixi Zhao

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Shi, X., Zhang, X., Huang, X., Zhang, R., Pan, S., Huang, S., Wang, Y., Ke, Y., Guo, W., Liu, X., Hao, Y., Li, Y., Zhao, X., Sun, Y., Li, J., Ma, H., & Zhao, X. (2024). N 6 ‐methyladenosine‐mediated upregulation of LNCAROD confers radioresistance in esophageal squamous cell carcinoma through stabilizing PARP1. Clinical and Translational Medicine, 14(10). https://doi.org/10.1002/ctm2.70039

Vancouver

Shi X, Zhang X, Huang X, Zhang R, Pan S, Huang S, et al. N 6 ‐methyladenosine‐mediated upregulation of LNCAROD confers radioresistance in esophageal squamous cell carcinoma through stabilizing PARP1. Clinical and Translational Medicine. 2024;14(10). doi:10.1002/ctm2.70039

BibTeX
@article{Shi2024,
  author = {Shi, Xiaobo and Zhang, Xiaozhi and Huang, Xinran and Zhang, Ruijuan and Pan, Shupei and Huang, Shan and Wang, Yuchen and Ke, Yue and Guo, Wei and Liu, Xiaoxiao and Hao, Yu and Li, You and Zhao, Xu and Sun, Yuchen and Li, Jing and Ma, Hongbing and Zhao, Xixi},
  title = {N 6 ‐methyladenosine‐mediated upregulation of LNCAROD confers radioresistance in esophageal squamous cell carcinoma through stabilizing PARP1},
  journal = {Clinical and Translational Medicine},
  year = {2024},
  volume = {14},
  number = {10},
  doi = {10.1002/ctm2.70039}
}
Kostenlos starten →